Graduate Studies Faculty
Sudarshan Anand, Ph.D.
Programs:Cell & Developmental Biology
Program in Molecular & Cellular Biosciences
Research Interests:MicroRNA, Cancer, Tumor Microenvironment, Cell Engineering » Click here for more about Dr. Anand's research » PubMed Listing
Preceptor RotationsAcademic Term Available Summer 2016 Maybe Fall 2016 Yes Winter 2016 Yes
Faculty MentorshipDr. Anand is available as a mentor for 2016-2017.
2007 Johns Hopkins University School of Medicine, Baltimore, MD
Ph.D. (Immunology). Mentor: Dr. Lieping Chen
2014- Assistant Professor, Cell & Developmental Biology,
Joint appointment with Radiation Medicine,
Oregon Health & Science University, Portland, OR
2014- Investigator, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
2013-2014 Assistant Research Scientist, Moores UCSD Cancer Center, San Diego, CA
2007-2013 Postdoctoral Scholar, Moores UCSD Cancer Center, San Diego, CA
Our lab (http://www.ohsu.edu/cdcb/anand) is broadly interested in understanding the role of non-coding RNAs in the tumor microenvironment. Specific long-term goals of the laboratory include:
1) miR networks & DNA damage in the tumor vasculature
The tumor microenvironment encounters a variety of insults during tumor progression including genotoxic stress. Understanding what factor(s) mediate stress responses in the host cells will a) provide potential targets for sensitizing the tumor microenvironment to genotoxic stress and b) contribute fundamental mechanistic insights into how the different host cell types in the microenvironment handle insults and injuries.
2) miR based cell engineering
We have identified specific miR programs that are sensitive to different stimuli and insults in the tumor microenvironment. One of our goals is to use miRs as tools to engineer cells that would eventually reprogram the tumor microenvironment.
3) non-coding RNAs and immune checkpoints
We are interested in identifying specific non-coding RNAs that can a) serve as reliable biosensors of these immune checkpoints and b) act as therapeutic targets to enhance the cell surface expression of co-stimulatory molecules or downregulate the expression of co-inhibitory molecules that will synergize with current antibody therapies.